Challenges & Innovations in CAR-T Therapy

Traditional CAR-T therapies rely on ex vivo T-cell engineering, but this approach presents challenges such as lengthy manufacturing cycles, high costs, and patient-specific variability. In vivo CAR-T therapy addresses these limitations by enabling direct CAR-T cell generation within the body through targeted delivery. This innovation has the potential to improve safety and efficacy, shorten treatment wait times, eliminate the need for lymphodepleting chemotherapy, and enhance patient convenience.

CAR-T Cells Inducing Cancer Cell Death

Comparison of In Vitro CAR-T Generation and In Vivo CAR-T Generation via Nano-Delivery Systems (Source: Xin et al., 2022)

RenNano® Platform: Driving In Vivo CAR-T Advancements

Leveraging Biocytogen’s proprietary RenNano® platform for fully human heavy-chain-only antibody (HCAb) discovery, we have developed high-specificity, high-affinity delivery systems to tackle key challenges in in vivo CAR-T development:

• Precision Targeting: HCAb-based modules selectively bind to T-cell surface markers (e.g., CD3/CD28), enabling efficient in vivo T-cell capture and genetic reprogramming.
• Efficient Delivery: Nanoscale antibody carriers seamlessly penetrate tissues, delivering mRNA/LNP or viral payloads across biological barriers to target cells.
• Enhanced Safety: Fully human antibody design minimizes immunogenicity, reducing the risk of anti-drug antibody (ADA) responses and expanding the therapeutic window.

HCAbs for In Vivo CAR-T Therapy at Biocytogen (Partial List)

Contact us today to explore evaluation, licensing, or co-development opportunities!